Trial Profile
An Open Phase I Clinical Study Assessing Safety and Tolerability of MVX-ONCO-1 in Patients With Solid Tumor Who Are Not/Not Any Longer Amenable to Standard Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 28 Oct 2022
Price :
$35
*
At a glance
- Drugs Cancer vaccine (Primary)
- Indications Bladder cancer; Brain cancer; Carcinoma; Cervical cancer; Colon cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Sarcoma; Small cell lung cancer; Soft tissue sarcoma; Thyroid cancer; Uterine cancer
- Focus Adverse reactions; First in man
- Acronyms MVX-ONCO
- Sponsors MaxiVax
- 13 Sep 2022 Interim results assessing safety and efficacy of MVX-ONCO in advanced relapsing solid tumors presented at the 47th European Society for Medical Oncology Congress
- 26 Jan 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2026.
- 26 Jan 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Mar 2022.